Genzyme acquistion of Bone Care approved, significant impact forecast
One of Wisconsin's most prominent pharmaceutical companies has been purchased, its stock delisted and its name changed. The move will result in a continued, but perhaps limited, presence in Wisconsin, create potential opportunites for the state's life science industry, increase distribution of their drug and...